SCHEMBL2404708

SCHEMBL2404708

CN(CCCNC(=O)C1=NOC2(CCN(S(=O)(=O)c3ccc(Cl)s3)CC2)C1)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.40
TDP1 Q9NUW8 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
PKM P14618 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MAPK1 P28482 1/20 0.39
ALDH1A1 P00352 5/20 0.38
MAPT P10636 3/20 0.38
TSHR P16473 2/20 0.38
GFER P55789 3/20 0.38
ATM Q13315 1/20 0.38
CNR1 P21554 1/20 0.37
THRB P10828 1/20 0.37
BCHE P06276 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
GAA P10253 2/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6409435 0.87 LMNA (0.38) LMNATDP1MEN1KMT2APKM
SCHEMBL2399881 0.83 LMNA (0.44) LMNATDP1MEN1KMT2APKM
SCHEMBL2400838 0.78 HTR6 (0.43) LMNATDP1PKMALDH1A1TSHR
SCHEMBL2400837 0.78 LMNA (0.43) LMNATDP1MEN1KMT2APKM
SCHEMBL6410614 0.77 LMNA (0.46) LMNATDP1KMT2ASMN1; SMN2MAPK1
SCHEMBL2404702 0.77 EPHX2 (0.41) LMNATDP1MEN1KMT2APKM
SCHEMBL2400618 0.77 SMN1; SMN2 (0.45) LMNATDP1MEN1KMT2ASMN1; SMN2
SCHEMBL2580957 0.76 ALDH1A1 (0.47) MEN1KMT2ASMN1; SMN2MAPK1ALDH1A1
SCHEMBL2400651 0.74 EPHX2 (0.45) LMNATDP1MEN1KMT2APKM
SCHEMBL2579299 0.73 LMNA (0.52) LMNAMEN1KMT2APKMSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224172-A1 Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods GRUENENTHAL GMBH (DE) 2011-09-15 US claimed
US-8048890-B2 Analgesics; neuropathic pain; headaches; muscle relaxants; incontence; tinnitus; diarrhea; antiarrhythmia agents; antiischemic agents; antiinflammatory agents; antiulcer agents; antidepressants; antiepileptic agents GRUENENTHAL GMBH (DE) 2011-11-01 US disclosed
US-20110224172-A1 Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods GRUENENTHAL GMBH (DE) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224172-A1 Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods SULT1E1, DECR1, CYP8B1 LMNA 1973/4885TDP1 3570/4885MEN1 2995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.